NCCN updates Clinical Practice Guidelines for Breast Cancer
October 07, 2015
Axel Ullrich's current research is set to contribute to the successful treatment of diabetes a second time. "Developing innovative drugs to treat diabetes gives us the opportunity to directly influence defects in the molecular signal paths, which lie at the root of diabetes. That enables us to fight the actual causes of diabetes," says Ullrich. Peter Gruss, President of the Max Planck Society expressed his delight with the collaboration agreement: "GlaxoSmithKline is one of the world's five major pharmaceutical companies. The collaboration agreement with GSK testifies to the fact that Max Planck Institutes, due to their leading edge in basic research, are also sought-after partners in industry. Max Planck researchers generate ideas for new approaches in application-oriented industrial research. We hope that together with a strong partner, we will be able to translate research findings into therapies which will enhance patient quality of life."
Prof Ullrich's longstanding expertise in molecular biology research is again being put to good use, having already resulted in some very successful therapeutic agents. For example, Herceptin-, a drug he developed, is successfully used to treat metastasised breast cancer. The drug Sutent-, which treats malignant tumours in the gastrointestinal tract (GIST) and renal cancer (MRCC) is also based on Ullrich's research work. In the case of both of the above drugs, the suppression of certain kinase activity with suitable inhibitors is central to the treatment.